Monitor renewal trends in 2026 as initial prescriptions approach expiration—this will be a key indicator of sustainable market share growth. Also watch for progress on unrestricted payor coverage and the impact of the expanded sales force and updated DTC campaign on prescription volume.
Price Chart
Executive Summary
ARS Pharmaceuticals reported full-year 2025 revenue of $84.3 million, driven by $72.2 million in U.S. net product revenue from its needle-free epinephrine spray neffy. Despite strong commercial progress, the company posted a net loss of $171.3 million due to high SG&A spending of $230.1 million, primarily on DTC marketing. It maintains a solid $245.0 million cash position, which it expects to fund operations through cash-flow break-even.
Key Financial Metrics
Key Facts
- Full-year 2025 revenue was $84.3 million, with $72.2 million from U.S. neffy sales.
- Net loss for 2025 was $171.3 million, or $1.74 per share, due to $230.1 million in SG&A expenses.
- Company has $245.0 million in cash, cash equivalents, and short-term investments as of December 31, 2025.
- Secured approvals for neffy in China and Australia in December 2025; CHMP positive opinion for EURneffy 1 mg in January 2026.
- Sales force to expand from 106 to 150 in Q2 2026 without increasing planned SG&A spend.
- More than 22,500 healthcare providers have prescribed neffy, with 50% being repeat prescribers.
Financial Impact
Revenue grew from $89.1 million in 2024 to $84.3 million in 2025, but net loss widened significantly due to commercial investment. SG&A increased 220% YoY to $230.1 million.
Risk Factors
- High SG&A spend may pressure margins if revenue growth does not accelerate.
- Dependence on payer reimbursement decisions; failure to secure unrestricted formulary access could limit adoption.
- Forward-looking statements about cash-flow break-even are uncertain and dependent on commercial execution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3251623 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 6d ago | 144 | $4.29 $4.18 | ▲ +2.56% | ▲ +3.09% | $4.03 (+6.06%) |
Sep 28, 2026 28d ago | Court Ruling | $4.40 $4.31 | ▼ −2.05% | ▼ −1.84% | $4.03 (−8.41%) |
Sep 16, 2026 5w ago | Court Ruling | $4.15 $4.11 | ▼ −0.96% | ▼ −0.84% | $4.03 (−2.89%) |
Aug 3, 2026 12w ago | Press Release | $5.46 $5.32 | ▼ −2.56% | ▼ −4.37% | $4.03 (−26.19%) |
Jul 17, 2026 14w ago | Court Ruling | $6.44 $6.36 | ▼ −1.24% | ▼ −2.08% | $4.03 (−37.42%) |
Jul 7, 2026 15w ago | 8-K | $8.10 $7.88 | ▼ −2.72% | ▼ −3.56% | $4.03 (−50.25%) |
Jun 12, 2026 19w ago | Insider Cluster | $9.81 $9.70 | ▼ −1.12% | ▼ −0.53% | $4.03 (−58.92%) |
May 15, 2026 23w ago | 8-K | $7.43 $7.30 | ▼ −1.68% | ▼ −1.62% | $4.03 (−45.72%) |
May 15, 2026 23w ago | Press Release | $7.43 $7.30 | ▲ +1.68% | ▲ +1.62% | $4.03 (+45.72%) |
May 13, 2026 23w ago | 8-K | $8.01 $7.94 | ▼ −0.87% | ▼ −1.65% | $4.03 (−49.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers